Chairman of the Board of Directors

Roy is an investor and businessman who has helped lead numerous global enterprises spanning the fields of advertising, aerospace, manufacturing, technology and finance. Bostock had a long and successful career in the advertising arena, which included engineering a merger to form the seventh largest global agency group, later acquired by Publicis Groupe in Paris. Bostock later was named Chairman of Northwest Airlines following its emergence from bankruptcy and helped architect the merger of Northwest and Delta Airlines, becoming Vice Chairman of Delta. Bostock also served as Chairman of Yahoo! Inc. and as a director of Morgan Stanley. Today, he is Chairman of his investment firm, Sealedge Investments, LLC. He graduated Phi Beta Kappa from Duke University, which he attended on a football scholarship and played both football and baseball while majoring in English literature. He earned an MBA from Harvard University.

CEO and Board of Directors

William is an experienced medical device executive specializing in medical design and business development. Cimino has over 25 years of professional experience in all aspects of medical device business, including device design and technology development, clinical studies and assessment, regulatory affairs, strategic market development, distribution, business management and growth, and funding. He has been directly responsible for the design and market introduction of over 50 medical products and has formed and run successful medical device startup companies. Dr. Cimino has been issued over 30 US patents and holds and PhD in Bioengineering, an MS in Mechanical Engineering, and a BS in Aerospace Engineering

VP Finance & Operations

Dale has 30 years of business leadership experience Dale has held executive and founding positions with venture- and angel-backed startups and has led operations, finance, IT, business development, and sales organizations at startup and large public companies. Most recently, Dale was a founding partner at NorthStone Group, LLC, where he worked with executive clients ranging from international Fortune 200 companies to venture-backed startups in the healthcare, medical device, financial service, and high-tech sectors. He has served as an interim executive for several clients. Dale has an MS from Washington State University.

Board of Directors

Morgan is the Managing Partner of Wyvern Capital and has been active in merchant banking and investment banking since 1978. He has originated, analyzed, structured, negotiated and syndicated approximately $40 billion of corporate transactions in the US, Europe, Asia, and Latin America. Mr. St. John has successfully assisted and collaborated with numerous investment groups including Manhattan Pacific Partners, Actian Capital, Boyer Capital, Washington Partners Wilson Partners, and Morpheus Capital. Prior to joining Wyvern Capital, Mr. St. John was a Partner and Managing Director at Banker Trust Company, where he built the Los Angeles Finance group and New York Syndication group to become industry leaders in highly structured acquisition financing. Mr. St. John has both his bachelor’s and master’s degrees from Harvard University.

Board of Directors

John Marous has led the development of new-start innovative technology businesses since 2002 as CEO of CarrierWeb, LLC (Atlanta, GA, 2003-2011) and CEO and Chairman of CardiacAsisst, Inc. (Pittsburgh, PA 2011-2018). As both businesses have exited to strategic entities, Mr. Marous is now involved in several new technology companies, serving as Chairman of HeartIO, Inc.(Pittsburgh, PA – artificial intelligence in diagnosis of heart disease), Chairman of IACtEx, LLC (Buffalo, NY – manufacturing management systems via internet of things connectivity), director of READA.ai Inc. (Pittsburgh, PA – artificial intelligence to detect stroke in situ during surgery), strategic advisor to Optimus Technologies, Inc. (Pittsburgh, PA – zero emission large trucks/vehicles), and strategic advisor to Heart Repair Technologies, Inc (San Jose, CA – percutaneous mitral valve repair). In the medical device field, he has served as head of R&D, head of Regulatory Affairs, head of Clinical Affairs, in addition to being the complete strategic sales responsibility, with the intent of managing promotion risks related to labeling. He has degrees of BS (in EE) from Cornell University in 1981 and MS from Carnegie Mellon University in 1985

Founder

Dr. Patrick is a world-renowned plastic surgeon known for his achievements in breast and aesthetic surgeries. A graduate of Vanderbilt University School of Medicine, he is a pioneer of microsurgery and the field of breast reconstruction. Dr. Maxwell invented the textured tissue expander (used worldwide for breast reconstruction for the last 20 years), worked with Allergan to create a series of breast implants, and developed “flap” procedures. He founded Baptist Hospital Institute for Aesthetic and Reconstructive Surgery in Nashville, Tennessee, has written over 100 scientific articles, and has lectured and performed live surgical demonstrations in over 20 countries. He holds 10 US patents (with seven more pending) for medical devices and has received numerous professional awards—most recently including the U.S. Congressional Recognition of Merit, Clinician of the Year Award by the American Association of Plastic Surgeons, and the Presidential Award from the American Society of Plastic Surgeons.

Nicholas Pachuda is a highly experienced life science executive committed to bringing transformational innovation to the clinic. He possesses deep clinical, technical, and business expertise with both multinationals and startups. He has operational leadership experience as a general manager with commercial P&L responsibility, as well as business development/external innovation and R&D and investment experience as a VC Venture Partner and PE Strategic Advisor. He has served as a startup board member and board advisor.

Dr. Pachuda’s professional experience includes: Peptilogics, Inc, Senior Vice President, Portfolio & Development; Johnson & Johnson, Vice President, External Innovation and Enabling Technologies, DePuy Synthes, Synthes Trauma (a Johnson & Johnson Company), Vice President Marketing and Business Development; Scient’x Spine—with HealthPoint Capital, Vice President Marketing, Professional Education, Clinical Affairs and Compliance; Small Bone Innovations, VP Business Development, Medical Education and Clinical Studies; Arthrex, Product Manager.  He holds a BS in Biology, Chemistry, History and Philosophy of Science from the University of Pittsburgh and a D.P.M. in podiatry from the Pennsylvania College of Podiatric Medicine.

Board of Directors, Founder

Dr. Katz is Professor of Plastic Surgery and Director of the Research Laboratory in the Department of Plastic and Reconstructive Surgery, Wake Forest School of Medicine. He is internationally recognized for his contributions, innovations, and expertise in the science and translation of adipose-derived cell therapies and fat grafting, including the development of device platforms that enable such. In addition to his scientific and entrepreneurial endeavours, he maintains a clinical practice that comprises both reconstructive and aesthetic surgery. He mentors and instructs students and residents at all levels in both the laboratory and clinical setting.

Founder

Ramon obtained his MD at University of Navarra, Spain, his PhD in cell biology and immunology from the University of California at Irvine, and a Diplomate from the European College of Transplantation. He served as chief of Plastic and Reconstructive Surgery at the MD Anderson Cancer Center in Madrid, Spain. Dr. Llull has received numerous awards and co-holds with Dr. Adam Katz several US and international patents related to tissue engineering, device biotechnology, and stem cells. He is a founder and past Chairman of the International Federation of Adipose Technologies and Science (IFATS), is a founder of StemSource, Inc., and enabled the first cell vaccine for brain tumors in Europe as a consultant of NorthWest BioTherapeutics. Dr. Llull is currently Director of STEM Center Mallorca, providing advanced regenerative therapies based on adipose biotechnology.

Board of Directors, Founder

J. William received his MD from Duke University, followed by General Surgery Residence at Case-Western Reserve University and Plastic Surgery Residency at Johns Hopkins University. He was a Clinical/Research Oncology Fellow in the Surgery Branch at the National Institutes of Health and is Board Certified in General Surgery and in Plastic and Reconstructive Surgery. He was Professor and Chief of Plastic Surgery at the University of Pittsburgh Medical Center for 21 years, is Past President of the American Association of Plastic Surgeons and multiple other medical organizations and is author or co-author of more than 200 peer-reviewed scientific publications. As an entrepreneur, he is co-inventor of multiple patents and co-founder of numerous businesses including CellSource, Inc.; StemSource, Inc.; Human Analytix, Inc.; Illumineer, Inc.; and Life Science Enhancement Corporation. He is currently Chairman and co-founder of The GID Group, Inc.

VP Global Business Development

Frank has worked in the healthcare industry for the past 30 years. During that time, he has held numerous senior executive positions focusing on sales and marketing, product development, operations, and general management. Frank has a strong global background and has built sales organizations in most of the key healthcare markets. Frank was the Global President of Sales for Systagenix Wound Management, where he reorganized the global sales structure while launching a number of key new products. Prior to Systagenix, Frank built the international business for Kinetic Concepts (KCI) and was responsible for the commercialization of the VAC technology (NWPT) which has grown to become a brand worth more than one billion dollars.

Director Clinical Affairs

Victoria began her tenure with GID BIO in 2015. She helped design a safety and feasibility trial and a pivotal trial to test GID’s stromal vascular fraction treatment for knee osteoarthritis. Her focus is on clinical trial design in support of therapeutic areas including osteoarthritis of the hand and shoulder; rheumatoid arthritis of the hand; diabetic ulcers; diabetic neuropathy; kidney fibrosis; and erectile dysfunction.

 Victoria has over 24 years of experience in medical device research with participation in over 50 publications including peer-reviewed journals and societal presentations on devices. She began her career conducting simulator testing of hip and knee implants at Loma Linda University before devoting the last 15 years to developing and managing clinical trials at Zeiss, Covidien, Sonoma Orthopedics and GID BIO for ophthalmic diagnostics; respiratory and monitoring devices; orthopedic implants; and cellular biologics.

Victoria earned a bachelor of science degree in physics from California State University – San Bernardino and a Ph.D. in bioengineering from Strathclyde University with an emphasis on orthopaedic tribology (study of wear, friction and lubrication).

Clinical Research Manager

Abby has spent the last five years of her career overseeing clinical studies at sites of varying sizes, including medical device startups and large universities. At GID BIO she is responsible for managing clinical research, from site review to initiation, to test the biotech company’s cellular therapy in studies with FDA clearance. Prior to joining GID, Abby oversaw six pivotal device trials; three device post-approval studies; and three investigator-initiated studies from the clinical site level at Washington University School of Medicine in St. Louis and University of Colorado – Anschutz Medical School; and a sponsor-level trial at Obalon Therapeutics. Abby earned a master of science degree in nutrition from Saint Louis University.

Clinical and Training Specialist